Duke University, Durham
Oral ZD6474 is well-tolerated in patients with advanced cancer
Published in Medicine and Law Weekly, October 14th, 2005
According to a study from the United States, "ZD6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor and epidermal growth factor receptor. The safety, tolerability and pharmacokinetics of ZD6474 were assessed in a phase I dose-escalation study of patients with advanced solid tumors."
"Adult patients with tumors refractory to standard treatments received once-daily oral ZD6474 (50-600 mg) in 28-day cycles, until disease progression or unacceptable toxicity was observed. Seventy-seven patients were treated at doses of 50 mg (n=9), 100 mg...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Albany Molecular Research, Inc.
Chemistry-based drug discovery firm adds three people to management team - Alnylam Pharmaceuticals, Inc.
Intellectual property licensed for MicroRNA gene involved in hepatitis C - Avitar, Inc.
U.S. patent secured for oral fluid DNA test - Barr Pharmaceuticals, Inc.
Letter of intent signed to acquire Mircette - Bioheart, Inc.
Two U.S. patents allowed regarding delivery systems - Competitive Technologies, Inc.
Carolina Liquid sued for patent infringement - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
